TransCode Therapeutics (RNAZ) Insider Trading & Ownership $1.37 -0.20 (-12.74%) Closing price 03/10/2025 04:00 PM EasternExtended Trading$1.38 +0.00 (+0.36%) As of 07:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TransCode Therapeutics (NASDAQ:RNAZ) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.80%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$142,560.00Number OfInsiders Selling(Last 3 Years)0 Get RNAZ Insider Trade Alerts Want to know when executives and insiders are buying or selling TransCode Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address RNAZ Insider Buying and Selling by Quarter Remove Ads TransCode Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/28/2023Robert Michael DudleyCEOBuy74$673.20$49,816.80 9/28/2023Thomas A FitzgeraldCFOBuy37$673.20$24,908.40 6/20/2023Robert Michael DudleyCEOBuy5$3,366.00$16,830.00 6/9/2023Robert Michael DudleyCEOBuy14$3,643.20$51,004.80 9/14/2022Robert Michael DudleyCEOBuy0$30,360.00$0.00 (Data available from 1/1/2013 forward) RNAZ Insider Trading Activity - Frequently Asked Questions Who is on TransCode Therapeutics's Insider Roster? The list of insiders at TransCode Therapeutics includes Robert Michael Dudley, and Thomas A Fitzgerald. Learn more on insiders at RNAZ. What percentage of TransCode Therapeutics stock is owned by insiders? 2.80% of TransCode Therapeutics stock is owned by insiders. Learn more on RNAZ's insider holdings. Which TransCode Therapeutics insiders have been buying company stock? The following insiders have purchased RNAZ shares in the last 24 months: Robert Michael Dudley ($117,651.60), and Thomas A Fitzgerald ($24,908.40). How much insider buying is happening at TransCode Therapeutics? Insiders have purchased a total of 130 RNAZ shares in the last 24 months for a total of $142,560.00 bought. TransCode Therapeutics Key ExecutivesMr. Thomas A. Fitzgerald M.B.A. (Age 72)Interim CEO, CFO, President, VP of Administration & Director Compensation: $358.14kDr. Philippe P. Calais Ph.D. (Age 65)Pharm., Pharm.D., Executive Chairman of the Board Compensation: $102.5kDr. Zdravka Medarova Ph.D. (Age 49)Co-Founder & Chief Scientific Officer Dr. Anna Moore Ph.D. (Age 62)Co-Founder, Scientific Advisor & Member of Scientific Advisory Board Ms. Susan Duggan M.B.A.R.N., Senior Vice President of OperationsDr. Daniel R. Vlock M.D. (Age 72)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Galecto Insider Trading GT Biopharma Insider Trading Moleculin Biotech Insider Trading Adial Pharmaceuticals Insider Trading Sonnet BioTherapeutics Insider Trading CERo Therapeutics Insider Trading Conduit Pharmaceuticals Insider Trading 180 Life Sciences Insider Trading Alzamend Neuro Insider Trading Kazia Therapeutics Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Scoop: 4 Stocks Insiders Are Buying and Selling2 Stocks Insiders Are Buying and 1 They're Selling3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in January This page (NASDAQ:RNAZ) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts